press-releases

Themis Bioscience completes Series A Financing round – EUR 5 Million to advance promising vaccine candidates

18 May 2011 – Themis Bioscience GmbH, an Austrian start-up biotechnology company developing novel vaccines against emerging infectious diseases with high unmet medical need announced today the closing of a EUR 5 Million Series A Financing round co-led by the international venture capital funds Ventech and Crédit Agricole Private Equity.

R&D alliance with Institut Pasteur to fight tropical infectious diseases

14 September 2010 – Themis Bioscience GmbH, an Austrian start-up biotechnology company developing vaccines against tropical infectious diseases, announced today the formation of a joint R&D program with Institut Pasteur, the Paris based world leading research institution.

Themis Bioscience secures additional public funding

1 July 2010 – The Austrian Research Promotion Agency (FFG) supports the companys further development with EUR 1 Million

Themis Bioscience successfully closes seed-financing round - EUR 1 Million for company start-up

contact

Series A Finance Round closed - 5 Mio. Euro for further product development
more
R&D alliance with Institut Pasteur Themis and Institut Pasteur join forces to fight tropical infectious diseases
more
New Labs and Offices: Themis Bioscience moves to TZM Muthgasse
more

imprint